Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy-Reference-Cited by-同舟云学术

Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy

Published:2007 Issue:4 Volume:25 Page:189-197
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol. Oncol.

Author:

Luminari Stefano,Cesaretti Marina,Rashid Ivan,Mammi Caterina,Montanini Antonella,Barbolini Elisa,Bellei Monica,Pennese Elsa,Sirotti Maria Angela,Marcheselli Luigi,Partesotti Giovanni,Bari Alessia,Maiorana Antonino,Bonacorsi Goretta,Federico Massimo

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference30 articles.

1. , , et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36(1): 69–86.

2. Global Cancer Statistics, 2002

3. Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis

4. Trends in Kaposi's Sarcoma and Non-Hodgkin's Lymphoma Incidence in the United States From 1973 Through 1998

5. Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019–2021;British Journal of Haematology;2024-02-23

2. Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy;AboutOpen;2023-10-02

3. Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020;Frontiers in Oncology;2023-07-18

4. Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018);Cancer Medicine;2023-04-19

5. Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy;AboutOpen;2023-01-16